SGLT2 Inhibitors and Progression of Chronic Kidney Disease in Patients with Elevated Lipoprotein(a): A Real-World Cohort Study
J Cardiovasc Pharmacol. 2026 May 11. doi: 10.1097/FJC.0000000000001835. Online ahead of print.ABSTRACTElevated lipoprotein(a) [Lp(a)] is a known risk factor for cardiovascular disease and may accelerate chronic kidney disease (CKD) progression. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have

